SB719: Bill Text

SB719,5 Section 5 . 49.45 (18) (b) 8. of the statutes is created to read:

SB719,8,12 49.45 (18) (b) 8. Prescription drugs.

SB719,6 Section 6 . 255.056 (2g) of the statutes is created to read:

SB719,8,19 255.056 (2g) The department may partner with out-of-state drug repository programs. The department may authorize a medical facility or pharmacy that elects to participate in the drug repository program to receive drugs or supplies from out of state, and the department may authorize an out-of-state entity that participates in a partner out-of-state drug repository program to receive drugs or supplies from Wisconsin.

SB719,7 Section 7 . 450.085 (3) of the statutes is created to read:

SB719,8,23 450.085 (3) An applicant for renewal of a license under s. 450.08 (2) (a) may count, for purposes of the continuing education requirement under sub. (1), up to 10 hours spent as a volunteer at a free and charitable clinic approved by the board.

SB719,8 Section 8 . 601.31 (1) (nv) of the statutes is created to read:

SB719,9,2 601.31 (1) (nv) For issuing or renewing a license as a pharmaceutical representative under s. 632.863, an amount to be set by the commissioner by rule.

SB719,9 Section 9 . 601.31 (1) (nw) of the statutes is created to read:

SB719,9,6 601.31 (1) (nw) For issuing or renewing a license as a pharmacy services administrative organization under s. 632.864, an amount to be set by the commissioner by rule.

SB719,10 Section 10 . 601.41 (13) of the statutes is created to read:

SB719,9,13 601.41 (13) Value-based diabetes medication pilot project. The commissioner shall develop a pilot project to direct a pharmacy benefit manager, as defined in s. 632.865 (1) (c), and a pharmaceutical manufacturer to create a value-based, sole-source arrangement to reduce the costs of prescription medication used to treat diabetes. The commissioner may promulgate rules to implement this subsection.

SB719,11 Section 11 . 601.415 (14) of the statutes is created to read:

SB719,9,20 601.415 (14) Patient pharmacy benefits tool. (a) From the appropriation under s. 20.145 (1) (a), beginning in the 2024-25 fiscal year, the office shall award grants in a total amount of up to $500,000 each fiscal year to health care providers to develop and implement a tool for prescribers to disclose the cost of prescription drugs for patients. The tool must be usable by physicians and other prescribers to determine the cost of prescription drugs for their patients.

SB719,9,22 (b) Any health care provider that receives a grant under par. (a) shall contribute matching funds equal to at least 50 percent of the grant amount awarded.

SB719,12 Section 12 . 601.575 of the statutes is created to read:

SB719,9,25 601.575 Prescription drug importation program. (1) Importation program requirements. The commissioner, in consultation with persons interested in the sale and pricing of prescription drugs and appropriate officials and agencies of the federal government, shall design and implement a prescription drug importation program for the benefit of residents of this state, that generates savings for residents, and that satisfies all of the following:

SB719,10,7 (a) The commissioner shall designate a state agency to become a licensed wholesale distributor or to contract with a licensed wholesale distributor and shall seek federal certification and approval to import prescription drugs.

SB719,10,9 (b) The program shall comply with relevant requirements of 21 USC 384, including safety and cost savings requirements.

SB719,10,11 (c) The program shall import prescription drugs from Canadian suppliers regulated under any appropriate Canadian or provincial laws.

SB719,10,13 (d) The program shall have a process to sample the purity, chemical composition, and potency of imported prescription drugs.

SB719,10,17 (e) The program shall import only those prescription drugs for which importation creates substantial savings for residents of this state and only those prescription drugs that are not brand-name drugs and that have fewer than 4 competitor prescription drugs in the United States.

SB719,10,19 (f) The commissioner shall ensure that prescription drugs imported under the program are not distributed, dispensed, or sold outside of this state.

SB719,10,20 (g) The program shall ensure all of the following:

SB719,10,22 1. Participation by any pharmacy or health care provider in the program is voluntary.

SB719,10,24 2. Any pharmacy or health care provider participating in the program has the appropriate license or other credential in this state.

SB719,11,3 3. Any pharmacy or health care provider participating in the program charges a consumer or health plan the actual acquisition cost of the imported prescription drug that is dispensed.

SB719,11,7 (h) The program shall ensure that a payment by a health plan or health insurance policy for a prescription drug imported under the program reimburses no more than the actual acquisition cost of the imported prescription drug that is dispensed.

SB719,11,9 (i) The program shall ensure that any health plan or health insurance policy participating in the program does all of the following:

SB719,11,11 1. Maintains a formulary and claims payment system with current information on prescription drugs imported under the program.

SB719,11,14 2. Bases cost-sharing amounts for participants or insureds under the plan or policy on no more than the actual acquisition cost of the prescription drug imported under the program that is dispensed to the participant or insured.

SB719,11,17 3. Demonstrates to the commissioner or a state agency designated by the commissioner how premiums under the plan or policy are affected by savings on prescription drugs imported under the program.

SB719,11,20 (j) Any wholesale distributor importing prescription drugs under the program shall limit its profit margin to the amount established by the commissioner or a state agency designated by the commissioner.

SB719,11,22 (k) The program may not import any generic prescription drug that would violate federal patent laws on branded products in the United States.

SB719,12,2 (L) The program shall comply with tracking and tracing requirements of 21 USC 360eee and 360eee-1, to the extent practical and feasible, before the prescription drug to be imported comes into the possession of this state's wholesale distributor and fully after the prescription drug to be imported is in the possession of this state's wholesale distributor.

SB719,12,4 (m) The program shall establish a fee or other mechanism to finance the program that does not jeopardize significant savings to residents of this state.

SB719,12,5 (n) The program shall have an audit function that ensures all of the following:

SB719,12,7 1. The commissioner has a sound methodology to determine the most cost-effective prescription drugs to include in the program.

SB719,12,9 2. The commissioner has a process in place to select Canadian suppliers that are high quality, high performing, and in full compliance with Canadian laws.

SB719,12,11 3. Prescription drugs imported under the program are pure, unadulterated, potent, and safe.

SB719,12,12 4. The program is complying with the requirements of this subsection.

SB719,12,14 5. The program is adequately financed to support administrative functions of the program while generating significant cost savings to residents of this state.

SB719,12,16 6. The program does not put residents of this state at a higher risk than if the program did not exist.

SB719,12,18 7. The program provides and is projected to continue to provide substantial cost savings to residents of this state.

SB719,12,21 (2) Anticompetitive behavior. The commissioner, in consultation with the attorney general, shall identify the potential for and monitor anticompetitive behavior in industries affected by a prescription drug importation program.

SB719,13,6 (3) Approval of program design; certification. No later than the first day of the 7th month beginning after the effective date of this subsection .... [LRB inserts date], the commissioner shall submit to the joint committee on finance a report that includes the design of the prescription drug importation program in accordance with this section. The commissioner may not submit the proposed program to the federal department of health and human services unless the joint committee on finance approves the proposed program. Within 14 days of the date of approval by the joint committee on finance of the proposed program, the commissioner shall submit to the federal department of health and human services a request for certification of the approved program.

SB719,13,14 (4) Implementation of certified program. After the federal department of health and human services certifies the prescription drug importation program submitted under sub. (3), the commissioner shall begin implementation of the program, and the program shall be fully operational by 180 days after the date of certification by the federal department of health and human services. The commissioner shall do all of the following to implement the program to the extent the action is in accordance with other state laws and the certification by the federal department of health and human services:

SB719,13,17 (a) Become a licensed wholesale distributor, designate another state agency to become a licensed wholesale distributor, or contract with a licensed wholesale distributor.

SB719,13,19 (b) Contract with one or more Canadian suppliers that meet the criteria in sub. (1) (c) and (n).

SB719,13,22 (c) Create an outreach and marketing plan to communicate with and provide information to health plans and health insurance policies, employers, pharmacies, health care providers, and residents of this state on participating in the program.

SB719,13,25 (d) Develop and implement a registration process for health plans and health insurance policies, pharmacies, and health care providers interested in participating in the program.

SB719,14,2 (e) Create a publicly accessible source for listing prices of prescription drugs imported under the program.

SB719,14,5 (f) Create, publicize, and implement a method of communication to promptly answer questions from and address the needs of persons affected by the implementation of the program before the program is fully operational.

SB719,14,7 (g) Establish the audit functions under sub. (1) (n) with a timeline to complete each audit function every 2 years.

SB719,14,9 (h) Conduct any other activities determined by the commissioner to be important to successful implementation of the program.

SB719,14,11 (5) Report. By January 1 and July 1 of each year, the commissioner shall submit to the joint committee on finance a report including all of the following:

SB719,14,13 (a) A list of prescription drugs included in the prescription drug importation program under this section.

SB719,14,16 (b) The number of pharmacies, health care providers, and health plans and health insurance policies participating in the prescription drug importation program under this section.

SB719,14,21 (c) The estimated amount of savings to residents of this state, health plans and health insurance policies, and employers resulting from the implementation of the prescription drug importation program under this section reported from the date of the previous report under this subsection and from the date the program was fully operational.

SB719,14,23 (d) Findings of any audit functions under sub. (1) (n) completed since the date of the previous report under this subsection.

SB719,14,25 (6) Rulemaking. The commissioner may promulgate any rules necessary to implement this section.

SB719,13 Section 13 . 609.83 of the statutes is amended to read:

SB719,15,4 609.83 Coverage of drugs and devices. Limited service health organizations, preferred provider plans, and defined network plans are subject to ss. 632.853, 632.861, and 632.895 (6) (b), (16t), and (16v).

SB719,14 Section 14 . 632.863 of the statutes is created to read:

SB719,15,6 632.863 Pharmaceutical representatives. (1) Definitions. In this section:

SB719,15,9 (a) “Health care professional” means a physician or other health care practitioner who is licensed to provide health care services or to prescribe pharmaceutical or biologic products.

SB719,15,11 (b) “Pharmaceutical” means a medication that may legally be dispensed only with a valid prescription from a health care professional.

SB719,15,14 (c) “Pharmaceutical representative” means an individual who markets or promotes pharmaceuticals to health care professionals on behalf of a pharmaceutical manufacturer for compensation.

SB719,15,18 (d) “Wholesale acquisition cost” means the most recently reported manufacturer list or catalog price for a brand-name or generic drug available to wholesalers or direct purchasers in the United States, before application of discounts, rebates, or reductions in price.

SB719,15,24 (2) Licensure. (a) No individual may act as a pharmaceutical representative in this state without being licensed by the commissioner as a pharmaceutical representative under this section. In order to obtain a license, the individual shall apply to the commissioner in the form and manner prescribed by the commissioner. The term of a license issued under this paragraph is one year and is renewable. The application to obtain or renew a license shall include all of the following information:

SB719,16,2 1. The applicant's full name, residence address and telephone number, and business address and telephone number.

SB719,16,3 2. A description of the type of work in which the applicant will engage.

SB719,16,4 3. The fee under s. 601.31 (1) (nv).

SB719,16,6 4. An attestation that the applicant meets the professional education requirements under sub. (3).

SB719,16,7 5. Proof that the applicant has paid any assessed penalties and fees.

SB719,16,8 6. Any other information required by the commissioner.

SB719,16,14 (b) The pharmaceutical representative licensed under par. (a) shall report, in writing, to the commissioner any change to the information submitted on an application under par. (a) or any material change to the pharmaceutical representative's business operations or to any information provided under this section. The pharmaceutical representative shall make the report no later than 4 business days after the change or material change occurs.

SB719,16,17 (c) A pharmaceutical representative licensed under par. (a) shall display the pharmaceutical representative's license during each visit with a health care professional.

SB719,16,22 (3) Professional education requirements. (a) In order to become initially licensed under sub. (2) (a), a pharmaceutical representative shall complete a professional education course as determined by the commissioner. A pharmaceutical representative shall, upon request, provide the commissioner with proof of the coursework's completion.

SB719,17,2 (b) In order to renew a license under sub. (2) (a), a pharmaceutical representative shall complete a minimum of 5 hours of continuing professional education courses. A pharmaceutical representative shall, upon request, provide the commissioner with proof of the coursework's completion.

SB719,17,6 (c) The professional education coursework required under pars. (a) and (b) shall include training in ethical standards, whistleblower protections, laws and rules applicable to pharmaceutical marketing, and other subjects that the commissioner may identify by rule.

SB719,17,8 (d) The commissioner shall regularly designate courses that fulfill the requirements under this subsection and publish a list of the designated courses.

SB719,17,13 (e) The professional education coursework required under this subsection may not be provided by the employer of a pharmaceutical representative or be funded, in any way, by the pharmaceutical industry or a 3rd party funded by the pharmaceutical industry. A provider of a course designated under par. (d) shall disclose any conflict of interest.

SB719,17,17 (4) Disclosure to commissioner. (a) No later than June 1 of each year, a pharmaceutical representative licensed under sub. (2) (a) shall provide to the commissioner, in the manner prescribed by the commissioner, all of the following information from the previous calendar year:

SB719,17,20 1. The total number of times the pharmaceutical representative contacted health care professionals in this state and the specialties of the health care professionals contacted.

SB719,17,24 2. For each contact with a health care professional in this state, the location and duration of the contact, the pharmaceuticals for which the pharmaceutical representative provided information, and the value of any item, including a product sample, compensation, material, or gift, provided to the health care professional.

SB719,18,3 (b) The commissioner shall publish the information received under par. (a) on the commissioner's website in a manner in which individual health care professionals are not identifiable by name or other identifiers.

SB719,18,9 (5) Disclosure to health care professionals. During each contact with a health care professional, a pharmaceutical representative licensed under sub. (2) (a) shall disclose the wholesale acquisition cost of any pharmaceutical for which the pharmaceutical representative provides information and the names of at least 3 generic prescription drugs from the same therapeutic class or, if 3 are not available, as many as are available for prescriptive use.

SB719,18,14 (6) Ethical standards. The commissioner shall promulgate rules that contain ethical standards for pharmaceutical representatives and shall publish the ethical standards on the commissioner's website. A pharmaceutical representative licensed under sub. (2) (a) shall comply with the ethical standards contained in the rules and may not do any of the following: